PathToScale: The PERSIST Trial

Who May Qualify: •Inclusion criteria for long-acting injectable cabotegravir for pre-exposure prophylaxis will be applied per Ministry of Health guidelines. Per Ministry of Health guidelines, the following populations will be prioritized for long-acting injectable cabotegravir for pre-exposure prophylaxis distribution, following individual risk assessment: Individuals who are 15+ years old AND either 1. Female sex workers (FSW) OR 2. Men who have sex with men (MSM) OR 3. Transgender individuals (TG) OR 4. Women and adolescent girls and young women (AGYW) presenting at STI services and/or family planning and/or HIV testing services OR 5. Breastfeeding women (BFW) OR 6. Male partners of female sex workers and/or Men at high risk for HIV and/or men presenting with a syndromic or lab-confirmed sexually transmitted infections. All individuals initiated on long-acting injectable cabotegravir for pre-exposure prophylaxis 15 years or above will be included in the passively enrolled sample. Who Should NOT Join This Trial: - Per Ministry of Health guidelines, exclusion criteria for long-acting injectable cabotegravir for pre-exposure prophylaxis includes: Those living with HIV-1 or evidence of possible acute HIV infection OR Those with a prior Hepatitis B diagnosis OR Those with a known history of severe side effects to Cabotegravir Long Acting OR Those unwilling or unable to return for 3-monthly HIV testing or 2-monthly counseling and safety monitoring visits OR Clients currently on multi-drug resistance tuberculosis (MDR-TB) medications OR Clients currently taking post-exposure prophylaxis. Always talk to your doctor about whether this trial is right for you.